Jundishapur Journal of Microbiology

Published by: Kowsar

Immunization with KMP11-NTGP96-GFP Fusion of Leishmania major Induced Th1 Platform Immune Response in Susceptible BALB/c mice

Abdolhossein Dalimi 1 , * and Vahid Nasiri 2
Authors Information
1 Parasitology Department, Faculty of Medical Sciences Faculty, Tarbiat Modares University, Tehran, IR Iran
2 Parasitology Department, Razi Vaccine and Serum Research Institute, Karaj, IR Iran
Article information
  • Jundishapur Journal of Microbiology: December 01, 2016, 9 (12); e36186
  • Published Online: October 9, 2016
  • Article Type: Research Article
  • Received: January 11, 2016
  • Revised: May 28, 2016
  • Accepted: October 2, 2016
  • DOI: 10.5812/jjm.36186

To Cite: Dalimi A, Nasiri V. Immunization with KMP11-NTGP96-GFP Fusion of Leishmania major Induced Th1 Platform Immune Response in Susceptible BALB/c mice, Jundishapur J Microbiol. 2016 ; 9(12):e36186. doi: 10.5812/jjm.36186.

Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Rodriguez-Cortes A, Ojeda A, Lopez-Fuertes L, Timon M, Altet L, Solano-Gallego L, et al. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine. 2007; 25(46): 7962-71[DOI][PubMed]
  • 2. Assreuy J, Cunha FQ, Epperlein M, Noronha-Dutra A, O'Donnell CA, Liew FY, et al. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol. 1994; 24(3): 672-6[DOI][PubMed]
  • 3. Ribeiro-Gomes FL, Moniz-de-Souza MC, Alexandre-Moreira MS, Dias WB, Lopes MF, Nunes MP, et al. Neutrophils activate macrophages for intracellular killing of Leishmania major through recruitment of TLR4 by neutrophil elastase. J Immunol. 2007; 179(6): 3988-94[PubMed]
  • 4. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 1994; 263(5144): 235-7[PubMed]
  • 5. Wang ZE, Reiner SL, Zheng S, Dalton DK, Locksley RM. CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. J Exp Med. 1994; 179(4): 1367-71[PubMed]
  • 6. Swihart K, Fruth U, Messmer N, Hug K, Behin R, Huang S, et al. Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J Exp Med. 1995; 181(3): 961-71[PubMed]
  • 7. Hurdayal R, Brombacher F. The role of IL-4 and IL-13 in cutaneous Leishmaniasis. Immunol Lett. 2014; 161(2): 179-83[DOI][PubMed]
  • 8. Alexander J, Satoskar AR, Russell DG. Leishmania species: models of intracellular parasitism. J Cell Sci. 1999; 112 Pt 18: 2993-3002[PubMed]
  • 9. Kropf P, Herath S, Weber V, Modolell M, Muller I. Factors influencing Leishmania major infection in IL-4-deficient BALB/c mice. Parasite Immunol. 2003; 25(8-9): 439-47[PubMed]
  • 10. Mohebali M, Khamesipour A, Mobedi I, Zarei Z, Hashemi-Fesharki R. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine. 2004; 22(29-30): 4097-100[DOI][PubMed]
  • 11. Mohebali M, Fallah E, Jamshidi S, Hajjaran H. Vaccine trial against canine visceral leishmaniasis in the Islamic Republic of Iran. East Mediterr Health J. 1998; 4(2): 234-8
  • 12. Mohebali M, Fallah E, Mobedi I, Hajjaran H. Field trial of autoclaved Leishmania vaccines for control of canine visceral leishmaniasis in Meshkin-shahr, Iran. Arch Inst Razi. 1999; 50: 87-92
  • 13. Barati M, Mohebali M, Alimohammadian MH, Khmesipour A, Keshavarz H, Akhoundi B, et al. Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania major (Alum-ALM) Vaccine Mixed With BCG Plus Imiquimod Vs. Placebo Control Group. Iran J Parasitol. 2015; 10(3): 351-9[PubMed]
  • 14. Locksley RM, Louis JA. Immunology of leishmaniasis. Curr Opin Immunol. 1992; 4(4): 413-8[PubMed]
  • 15. Das S, Freier A, Boussoffara T, Das S, Oswald D, Losch FO, et al. Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci Transl Med. 2014; 6(234): 234ra56[DOI][PubMed]
  • 16. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med. 1997; 186(7): 1137-47[PubMed]
  • 17. Ramos I, Alonso A, Peris A, Marcen JM, Abengozar MA, Alcolea PJ, et al. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection. Vaccine. 2009; 27(48): 6695-703[DOI][PubMed]
  • 18. Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun. 2002; 70(6): 2828-36[PubMed]
  • 19. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine. 2005; 23(28): 3716-25[DOI][PubMed]
  • 20. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol. 2005; 174(11): 7160-71[PubMed]
  • 21. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun. 2005; 73(2): 812-9[DOI][PubMed]
  • 22. Sasaki S, Takeshita F, Xin KQ, Ishii N, Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods. 2003; 31(3): 243-54[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments